Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 114B 410M 358M 331M 305M 575M 39.5B 587M 3.95B 1.56B 19.35B 1.54B 1.51B 66.6B P/E 2026 *
10.4x
P/E 2027 * 8.86x
Enterprise Value 114B 410M 358M 331M 305M 575M 39.5B 587M 3.95B 1.56B 19.35B 1.54B 1.51B 66.6B EV / Sales 2026 *
1.66x
EV / Sales 2027 * 1.53x
Free-Float
16.89%
Yield 2026 *
5.14%
Yield 2027 * 5.82%
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
06-01 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
04-07 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
03-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
03-26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
24/10/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
02/09/25 GlaxoSmithKline Pakistan Limited Declares Interim Cash Dividend for the Half Year Ended June 30, 2025 CI
26/08/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-0.66%
1 week-4.09%
Current month-3.38%
1 month-5.17%
3 months-9.08%
6 months-16.60%
Current year-8.22%
1 week 349
Extreme 349
369.9
1 month 349
Extreme 349
393
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Director of Finance/CFO - 01/06/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 72 02/04/2020
Director/Board Member - 05/12/2018
Director/Board Member - 01/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%-4.09%-8.84%+347.19% 410M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.13%+0.26%+24.80%+83.24% 357.55B
Weighted average by Cap. +0.37%+0.02%+37.50%+79.66%

Financials

2026 *2027 *
Net sales 68.81B 248M 217M 200M 184M 347M 23.86B 355M 2.39B 939M 11.69B 930M 910M 40.23B 74.58B 269M 235M 217M 200M 376M 25.86B 385M 2.59B 1.02B 12.66B 1.01B 986M 43.6B
Net income 10.49B 37.77M 33.01M 30.46M 28.07M 52.91M 3.64B 54.09M 364M 143M 1.78B 142M 139M 6.13B 12.42B 44.72M 39.08M 36.06M 33.24M 62.65M 4.31B 64.04M 431M 170M 2.11B 168M 164M 7.26B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
17/07/26 PKR 357.75 -0.66% 130,207
16/07/26 PKR 360.14 +2.13% 270,467
15/07/26 PKR 352.64 -0.10% 231,416
14/07/26 PKR 353.00 -3.57% 746,000
13/07/26 PKR 366.07 -1.86% 187,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
357.75PKR
Average target price
517.50PKR
Spread / Average Target
+44.65%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock